{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:39:21Z","timestamp":1760240361127,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Background: Cardiac collagen remodeling is important in the progression of heart failure. Estimation of cardiac collagen turnover by serum levels of serological markers is used for monitoring cardiac tissue repair and fibrosis. Peritoneal dialysis (PD) is used for the long-term management of refractory congestive heart failure (CHF). In this study, we investigated the effect of PD treatment on circulating fibrosis markers levels in patients with refractory CHF and fluid overload. Methods: Twenty-five patients with refractory CHF treated with PD were prospectively enrolled in the study. Circulating fibrosis markers procollagen type III C-peptide (PIIINP), matrix metalloproteinase 2 (MMP-2), and tissue inhibitor of metalloproteinases I (TIMP-1) levels were checked at baseline and after three and six months of treatment. Results: The clinical benefit of PD manifested by improved NYHA functional class and reduced hospitalization rate. Serum brain natriuretic peptide (BNP) levels decreased significantly during the treatment. Serum MMP-2 and TIMP-1 decreased significantly on PD. Circulating PIIINP showed two patterns of change, either decreased or increased following PD treatment. Patients in whom circulating PIIINP decreased had significantly lower baseline serum albumin, lower baseline mean arterial blood pressure, higher serum CRP, and a less significant improvement in hospitalization rate compared to the patients in whom circulating PIIINP increased. Patients in whom all three markers decreased demonstrated a trend to longer survival compared to patients whose markers increased or did not change. Conclusion: In refractory CHF patients PD treatment was associated with a reduction in circulating fibrosis markers.<\/jats:p>","DOI":"10.3390\/ijms20112610","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:18:09Z","timestamp":1559042289000},"page":"2610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure"],"prefix":"10.3390","volume":"20","author":[{"given":"Margarita","family":"Kunin","sequence":"first","affiliation":[{"name":"Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Hashomer 52621, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vered","family":"Carmon","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Hashomer 52621, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pazit","family":"Beckerman","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Hashomer 52621, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dganit","family":"Dinour","sequence":"additional","affiliation":[{"name":"Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Hashomer 52621, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.109.912774","article-title":"Circulating biomarkers of collagen metabolism in cardiac diseases","volume":"121","author":"Lopez","year":"2010","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.biocel.2007.12.006","article-title":"The regulation of matrix metalloproteinases and their inhibitors","volume":"40","author":"Clark","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/01.RES.0000013290.12884.A3","article-title":"Matrix metalloproteinases: Regulation and dysregulation in the failing heart","volume":"90","author":"Spinale","year":"2002","journal-title":"Circ. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2004.07.023","article-title":"Matrix metalloproteinases and their tissue inhibitors in pressure overloaded human myocardium during heart failure progression","volume":"44","author":"Polyakova","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.2042-7158.2010.01241.x","article-title":"Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure","volume":"63","author":"Song","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/eurjhf\/hfs179","article-title":"Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure","volume":"15","author":"Kaye","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejheart.2008.02.015","article-title":"Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality","volume":"10","author":"Frantz","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ahj.2004.11.016","article-title":"Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure","volume":"150","author":"George","year":"2005","journal-title":"Am. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejheart.2003.05.002","article-title":"Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure","volume":"6","author":"Yamazaki","year":"2004","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1253\/circj.68.355","article-title":"Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction","volume":"68","author":"Noji","year":"2004","journal-title":"Circ. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.105.573865","article-title":"Matrix metalloproteinases\/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease","volume":"113","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ehj.2004.05.029","article-title":"Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: The Framingham heart study","volume":"25","author":"Evans","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000430084","article-title":"Peritoneal Dialysis for Chronic Congestive Heart Failure","volume":"40","author":"Ronco","year":"2015","journal-title":"Blood Purif."},{"key":"ref_17","unstructured":"Kunin, M., Carmon, V., Arad, M., Levin-Iaina, N., Freimark, D., Holtzman, E.J., and Dinour, D. (2015). Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. Biomed. Res. Int., 2015."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000321102","article-title":"Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure","volume":"30","author":"Cnossen","year":"2010","journal-title":"Blood Purif."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ndt\/gfp484","article-title":"Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure","volume":"25","author":"Sanchez","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CN107026","article-title":"Peritoneal dialysis for patients suffering from severe heart failure","volume":"76","author":"Sotirakopoulos","year":"2011","journal-title":"Clin. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000351202","article-title":"Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: Potential Prognostic Factors","volume":"35","author":"Kunin","year":"2013","journal-title":"Blood Purif."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/cphy.c140045","article-title":"Extracellular matrix communication and turnover in cardiac physiology and pathology","volume":"5","author":"Takawale","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.ijo.0803022","article-title":"Myocardial collagen turnover in normotensive obese patients: Relation to insulin resistance","volume":"29","author":"Quilliot","year":"2005","journal-title":"Int. J. Obes. (Lond)"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1755-5922.2010.00247.x","article-title":"Myocardial reverse remodeling","volume":"30","author":"Hellawell","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/hy1101.099484","article-title":"Treatment of Congestive Heart Failure Interfering the Aldosterone-Cardiac Extracellular Matrix Relationship","volume":"38","author":"Zannad","year":"2001","journal-title":"Hypertension"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/13547500801903123","article-title":"Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat","volume":"13","author":"Kramer","year":"2008","journal-title":"Biomarkers"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0735-1097(01)01408-5","article-title":"Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction","volume":"38","author":"Dries","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2003.11.024","article-title":"Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure","volume":"43","author":"Gustafsson","year":"2004","journal-title":"Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/1354750X.2015.1118539","article-title":"Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis","volume":"21","author":"Morine","year":"2016","journal-title":"Biomarkers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1096\/fasebj.5.8.1850705","article-title":"Matrix metalloproteinases and their inhibitors in connective tissue remodeling","volume":"131","author":"Woessner","year":"1991","journal-title":"FASEB J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0163-7258(93)90074-N","article-title":"Tissue inhibitor of metalloproteinases (TIMP aka EPA): Structure, control of expression and biological functions","volume":"59","author":"Denhardt","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/HYPERTENSIONAHA.117.09045","article-title":"Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63\u2013Integrin \u03b21 Interaction","volume":"69","author":"Takawale","year":"2017","journal-title":"Hypertension"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4615-5385-4_4","article-title":"Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease","volume":"432","author":"Funck","year":"1997","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0167-4889(95)00205-7","article-title":"Angiotensin II induces TIMP-1 production in rat heart endothelial cells","volume":"1311","author":"Chua","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.HYP.35.6.1197","article-title":"Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats","volume":"35","author":"Varo","year":"2000","journal-title":"Hypertension"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fphys.2017.00777","article-title":"The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis","volume":"8","author":"Murtha","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(16)30508-6","article-title":"The heart and vascular system in dialysis","volume":"388","author":"Wanner","year":"2016","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology","volume":"116","author":"Cooper","year":"2007","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/11\/2610\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:54:02Z","timestamp":1760187242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/11\/2610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ijms20112610"],"URL":"https:\/\/doi.org\/10.3390\/ijms20112610","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2019,5,28]]}}}